TNFSF15 monoclonal antibody, clone VEGI/1283

Catalog # MAB14902 Size 100 ug

Applications



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)

Immunohistochemical staining (Formalin-fixed paraffin-embedded sections) of (A) human colon carcinoma and (B) human parathyroid mass with TNFSF15 monoclonal antibody, clone VEGI/1283 (Cat # MAB14901).

Specification

Product Description	Mouse monoclonal antibody raised against full length recombinant human TNFSF15.
Immunogen	Recombinant protein corresponding to full-length human TNFSF15.
Host	Mouse
Reactivity	Human
Form	Liquid
Purification	Protein A/G purification
Isotype	IgG1, kappa

Copyright © 2023 Abnova Corporation. All Rights Reserved.

Recommend Usage	Flow Cytometry (0.5-1 ug/million cells) Immunofluorescence (1-2 ug/mL) Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (1-2 ug/mL) Western Blot (1-2 ug/mL) The optimal working dilution should be determined by the end user.
Storage Buffer	In 10 mM PBS.
Storage Instruction	Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing.

Applications

- Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)

  Immunohistochemical staining (Formalin-fixed paraffin-embedded sections) of (A) human colon carcinoma and (B) human parathyroid mass with TNFSF15 monoclonal antibody, clone VEGI/1283 (Cat # MAB14901).

- Immunofluorescence
- Flow Cytometry
- Western Blot

Gene Info — TNFSF15

Entrez GeneID	9966
Gene Name	TNFSF15
Gene Alias	MGC129934, MGC129935, TL1, TL1A, VEGI, VEGI192A
Gene Description	tumor necrosis factor (ligand) superfamily, member 15
Omim ID	604052
Gene Ontology	Hyperlink
Gene Summary	The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) lig and family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a li gand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB an d MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cyto kine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. An additional isoform encoded by an alternatively spliced transcript variant has been rep orted but the sequence of this transcript has not been determined. [provided by RefSeq

Copyright © 2023 Abnova Corporation. All Rights Reserved.

Other Designations	OTTHUMP00000022739|TNF ligand-related molecule 1|TNF superfamily ligand TL1A|vascular endothelial cell growth inhibitor|vascular endothelial growth inhibitor-192A

Publication Reference

- Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients.

  Parr C, Gan CH, Watkins G, Jiang WG.

  Angiogenesis 2006 Jun; 9(2):73.

  Application: IHC-Fr, WB-Ce, Human, ZR-75-1, BT-474, BT-549, MCF-7, MDA-MB-231, MDA-MB-435S, MDA-MB- 436, MDA-MB- 157, MDA-MB- 453 cells, Breast

- Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily.

  Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL, Li LY.

  International Journal of Cancer 1999 Jul; 82(1):131.

  Application: ELISA, Hamster, CHO cells

- VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.

  Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL.

  FASEB Journal 1999 Jan; 13(1):181.

Pathway

- Cytokine-cytokine receptor interaction

Disease

- Colitis
- Crohn Disease
- Diabetes Mellitus
- Disease Progression
- Disease Susceptibility

Copyright © 2023 Abnova Corporation. All Rights Reserved.

- Genetic Predisposition to Disease
- Inflammatory Bowel Diseases
- Leprosy
- Rectal Fistula

Copyright © 2023 Abnova Corporation. All Rights Reserved.